Esperion Therapeutics, Inc. 8-K

What Happened

• Esperion Therapeutics, Inc. announced it completed the merger to acquire Corstasis Therapeutics Inc. on April 2, 2026 pursuant to a Merger Agreement dated March 2, 2026. The upfront cash consideration was $75,000,000 (subject to customary adjustments and a post-closing purchase price adjustment). Corstasis equityholders may receive up to $180,000,000 in future milestones plus royalty/licensing‑revenue–linked payments.
• Concurrently on April 2, 2026 Esperion amended its existing Credit Agreement to incur $25,000,000 of additional term loans (borrowed in full at closing) and entered a $50,000,000 Royalty Purchase Agreement with Athyrium Opportunities IV Acquisition LP to sell a portion of certain royalties and milestone receipts tied to Bempedoic Acid and other licensed products in the Otsuka Territory.

Key Details

• Merger close date: April 2, 2026; Merger Agreement executed March 2, 2026.
• Upfront purchase price: $75,000,000 in cash (plus customary adjustments); contingent milestone potential up to $180,000,000.
• New financing: $25,000,000 in term loans added to Esperion’s Credit Agreement and borrowed in full on the closing date; these loans carry the same terms as existing term loans.
• Royalty sale: $50,000,000 received from Athyrium in exchange for 100% of specified Receivables (royalties and certain milestones) in the Otsuka Territory until Athyrium has received $100,000,000, after which those Receivables revert to Esperion.
• Prepayment/call protection: if term loans are prepaid (other than scheduled amortization), premiums apply — make-whole (interest through 2nd anniversary) + 3% if prepaid on/ before 2nd anniversary; 3% between years 2–3; 1% between years 3–4; none after year 4.

Why It Matters

• The acquisition expands Esperion’s assets and potential future revenue streams (upfront payment plus up to $180M in milestones and future royalty/licensing payments).
• Financing and monetization: Esperion raised immediate cash via a $25M term loan and a $50M royalty sale to fund the transaction and related needs. The royalty sale provides near‑term liquidity but transfers specified future royalty and milestone receipts to the purchaser until it collects $100M, reducing near‑term upside from those Receivables.
• Debt and flexibility: the additional term loan increases debt exposure and includes prepayment penalties for the first four years, which may affect Esperion’s ability to refinance or repay the loans early without paying premiums.